CompletedNCT03247543
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD
Medication studyAges 6–11United States
Understand this study
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 11 years. Other eligibility criteria applied.
- Listed locations
- Long Beach, United States · Lauderhill, United States and 8 more locationsSee all locations and recruitment
- Activities
- Placebo comparator · Medication described in the protocol
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateStarted: October 31, 2017
- Recruitment status
- Completed
- Enrollment listed in the registry
- 313
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 6 Years to 11 Years
- Official registry ID
- NCT03247543
- Official title
Show the full official title
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) 200 and 400 mg Efficacy and Safety in Children With ADHD - A Double-Blind, Placebo-Controlled, Pivotal Trial
Recruitment & locations
CompletedLong Beach · Lauderhill · Orlando
7 more locations
- Tampa
- Overland Park
- Oklahoma City
- Charleston
- Austin
- Houston
- Clinton
Questions about this study
Who is behind this study?
The study sponsor is Supernus Pharmaceuticals, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Placebo, 200mg SPN-812 and 400mg SPN-812.
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 11 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )
A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)